EudraCT Number:,Sponsor Protocol Number:,Sponsor Name:,Full Title:,Start Date:,Medical condition:,Disease 1:,Population Age:,Gender:,Trial protocol:,Link:,Disease:,Disease 2:,Disease 3:,Disease 4:,COVID-19
2020-001331-26,PROLIFIC2020,Cambridge University Hospitals NHS Foundation Trust,ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial),2020-04-14,"Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2","Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001331-26,,,,,
2020-001402-38,CTU/2020/352,University College London,"An international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in healthcare workers.",2020-10-20,"Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection","Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001402-38,,,,,
2020-001889-10,STOIC,"University of Oxford, Clinical Trials and Research Governance",Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation,2020-06-02,COVID 19,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001889-10,,,,,
2020-001777-71,RAVEN,Guy’s and St Thomas' NHS Foundation Trust,Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN,2020-05-06,Severe COVID-19 infection with risk of need for mechanical ventilation.,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001777-71,,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",,,
2020-001740-26,ATOMIC2,"University of Oxford, Clinical Trials and Research Governance",A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2),2020-05-05,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001740-26,,"Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10070255, Term: Coronavirus test positive, Level: PT",,,
2020-002110-41,CRUKD/20/002,Cancer Research UK,"SPIKE-1 TRIAL: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated memb...",2020-06-18,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002110-41,,,,,
2020-001597-30,MRx-4DP0004-II-001,4D pharma plc,"A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)",2020-05-29,Symptoms of Covid-19 infection,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10061986, Term: SARS, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001597-30,,,,,
2020-001750-22,20HH5926,Joint Research Compliance Office,"MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia",2020-07-09,COVID-19 pneumonia,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001750-22,,,,,
2020-001448-24,RG_20-029COVID-19,University of Birmingham,Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 ,2020-04-15,Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19,"Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035664, Term: Pneumonia, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24,,"Version: 21.1, SOC Term: 100000004855, Classification Code: 10003083, Term: ARDS, Level: LLT",,,
2020-001721-31,SPON-AK-0420,Hampshire Hospitals NHS TRust,Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals?,2020-05-01,Covid-19,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10061986, Term: SARS, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001721-31,,,,,
2020-003628-18,000000,"University of Oxford, Clinical Trials and Research Governance",Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial,2020-09-29,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003628-18,,"Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10070255, Term: Coronavirus test positive, Level: PT",,,
2020-001937-11,132333,University College London,"A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised p...",2020-04-30,Respiratory illness caused by Covid-19,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001937-11,,,,,
2020-001904-41,GETAFIX-2020,NHS Greater Glasgow and Clyde,Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients,2020-05-20,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adolescents, Under 18, Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001904-41,,,,,
2020-005395-35,GatesMRI-COD-01-T01-01,Bill & Melinda Gates Medical Research Institute,"A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19 ",2020-12-16,"Mild COVID-19 in people who are at high risk for moderate or severe disease due to age, body mass index (BMI) and comorbidities, many of which are also thrombotic risks. ",,,,,,,,,,
,,,,,,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005395-35,,,,,
2020-002120-37,RESP301-002,Thirty Respiratory Limited,"An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with C...",2020-06-16,Coronavirus disease 2019 (COVID-19) ,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10061986, Term: SARS, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002120-37,,,,,
2020-001072-15,COV001,University of Oxford,"A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers",2020-03-26,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",Adults,"Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001072-15,,,,,
2020-004123-16,2019nCoV-302,"Novavax, Inc.","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ ...",2020-09-23,Prevention of COVID-19 caused by SARS-CoV-2,"Version: 23.1, SOC Term: 100000004865, Classification Code: 10084465, Term: COVID-19 vaccination, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004123-16,,,,,
2020-001502-38,VP-C21-006,Vicore Pharma AB,"A randomised, double blind, placebo controlled, Phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation ",2020-05-06,Covid-19 infection,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001502-38,,,,,
2020-001209-22,PRINCIPLE,University of Oxford / Clinical Trials and Research Governance ,Platform Randomised trial of INterventions against COVID-19 In older peoPLE,2020-03-26,Suspected COVID-19,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001209-22,,,,,
2020-001640-26,132151,University College London,"A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial  ",2020-04-17,Acute respiratory distress syndrome (ARDS) caused by COVID-19 ,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001640-26,,,,,
2020-001886-35,RHMCRI0399,University Hospital Southampton NHS Foundation Trust,A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults,2020-05-15,COVID-19 infection in patients requiring endotrachael intubation,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001886-35,,,,,
2020-002476-13,20HH5958,Imperial College London,A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. ,2020-07-24,Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ...,"Version: 20.0, SOC Term: 100000004857, Classification Code: 10023417, Term: Kidney dysfunction, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002476-13,,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10047463, Term: Viral infection NOS, Level: LLT","Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10063321, Term: Interleukin level, Level: PT","Version: 20.1, SOC Term: 10041244 - Social circumstances, Classification Code: 10079637, Term: Dependence on oxygen therapy, Level: PT",
2020-004144-28,CCTU0307,Cambridge university Hosptials NHS Foundation Trust and University of Cambridge,PROphylaxis for paTiEnts at risk of COVID-19 infecTion,2020-10-23,,,,,GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004144-28,,,,,
2020-004994-27,2020SW03,Ashford and St Peter's Hospitals NHS Foundation Trust,Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection,2020-12-16,COVID-19,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004994-27,,,,,
2020-001805-21,RA486120,University Hospital Coventry & Warwickshire,"Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 ",2020-05-15,Sars-Cov-2,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001805-21,,,,,
2020-001228-32,COV002,CTRG,"A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19",2020-05-04,SARS-CoV-2,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001228-32,,,,,
2020-001449-38,CW002,Chelsea and Westminster Hospital NHS Foundation Trust,A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe ,2020-04-29,COVID-19 Infection,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38,,,,,
2020-002567-57,1.0,University of Oxford / Clinical Trials and Research Governance,To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support,2020-11-23,Covid-19,"Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001053, Term: Acute respiratory failure, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002567-57,,,,,
2020-002668-29,132796,University College London,A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX)  ,2020-06-25,COVID-19,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29,,,,,
2020-001996-33,CD12_COVID-19,"CytoDyn, Inc.","A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (CO...",2020-08-26,Coronavirus Disease 2019 (COVID-19),"Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001996-33,,,,,
2020-002106-68,CTU/2020/354,University College London Comprehensive Clinical Trial Unit,"Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19",2020-07-16,SARS-CoV-2 (Corona virus) infection,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002106-68,,,,,
2020-001643-13,01.01.20,University of Dundee,A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 ,2020-05-15,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adolescents, Under 18, Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001643-13,,,,,
2020-002230-32,,University of Edinburgh,Rapid Experimental Medicine for COVID-19 ,2020-06-23,COVID-19,,"Under 18, Adults","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002230-32,,,,,
2020-001636-95,282110,University of Manchester,Subcutaneous and Intravenous anakinra in COVID-19 Infection -  Feasibility & Pharmacokinetics/ Pharmacodynamics study,2020-05-20,Suspected or confirmed SARS-CoV-2 infection (confirmed by RNA-PCR),"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001636-95,,,,,
2020-002229-27,TACTIC-E,Cambridge University Hospitals NHS Foundation Trust,mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Experimental drugs and mechanisms  ,2020-06-09,SARS-Cov-2,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002229-27,,,,,
2020-001023-14,SG016,Synairgen Research Limited,A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectio...,2020-03-17,COVID-19,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14,,,,,
2020-004719-28,D8850C00003,AstraZeneca AB,"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...",2020-11-20,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004719-28,,,,,
2020-001786-36,ILIAD-7-UK-Cohort,RevImmune SAS France,Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”,2020-05-06,Lymphopenia and T cell exhaustion in  COVID-19 patients,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001786-36,,,,,
2020-001354-22,TACTIC-R,Cambridge University Hospitals NHS Foundation Trust,Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R),2020-05-06,COVID-19-related complications,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001354-22,,,,,
2020-001473-79,ESR-20-20653,"Saint Luke’s Hospital of Kansas City, Kansas City, Missouri, USA","An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19",2020-05-07,Respiratory Failure in patients with COVID-19,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001473-79,,,,,
2020-001860-27,UoL001542,University of Liverpool,AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment,2020-05-12,"Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2)","Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001860-27,,,,,
2020-001684-89,RG_20-030,University of Birmingham,CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.,2020-05-05,COVID-19,"Version: 20.1, SOC Term: 100000004855, Classification Code: 10047468, Term: Viral lower respiratory tract infections, Level: HLT","Adolescents, Under 18, Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001684-89,,,,,
2020-001203-16,LIBERATE,Guy's and St Thomas' NHS Foundation Trust,"Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial",2020-05-06,COVID-19; respiratory failure; hypoxaemia.,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001203-16,,"Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001053, Term: Acute respiratory failure, Level: PT","Version: 20.0, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10021141, Term: Hypoxaemia, Level: LLT",,
2020-001113-21,NDPHRECOVERY,University of Oxford,Randomised Evaluation of COVID-19 Therapy (RECOVERY),2020-03-17,COVID-19 (infection with SARS-CoV-2 virus),"Version: 21.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035737, Term: Pneumonia viral, Level: PT","Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21,,"Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10061982, Term: Severe acute respiratory syndrome, Level: PT",,,
2020-002952-18,Protocol,Ashford and St Peter's Hospitals NHS Foundation Trust,Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19),2020-07-21,Confirmed Covid-19 infection by RT-PCR,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002952-18,,,,,
2020-000483-27,CCT38473,"St.  Joseph’s  Healthcare,  McMaster  University",Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis in ICU,2020-11-19,critical illness requiring mechanical ventilation,,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000483-27,,,,,
2020-001396-33,EPA-COV-001,SLA Pharma (UK) Ltd,"A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2",2020-11-13,SARS-CoV-2,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10084272, Term: SARS-CoV-2 infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001396-33,,,,,
2020-002494-10,,Queen Mary University of London,Personalised Electronic Record Supported OptimisatioN when ALone  for Patients with Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic ,2020-07-17,Hypertension,"Version: 21.1, SOC Term: 100000004866, Classification Code: 10081425, Term: Arterial hypertension, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002494-10,,,,,
2020-001736-95,"ACCORD-2-001,Sub002,003,006",University Hospital Southampton NHS Foundation Trust,"ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients ",2020-04-28,COVID 19 ,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95,,,,,
2020-003486-19,1.002.20,University of Dundee,"A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con...",2020-10-08,Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection,"Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10066724, Term: Acute pneumonia, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003486-19,,"Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10010120, Term: Community acquired pneumonia, Level: LLT","Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084380, Term: COVID-19 pneumonia, Level: PT","Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001052, Term: Acute respiratory distress syndrome, Level: PT",
2020-001441-39,VIR20001,University of Oxford,"Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)",2020-05-12,"COVID-19, acute respiratory illness","Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) IT(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001441-39,,,,,
2020-002503-19,62586,UMC Utrecht,BCG vaccination to Reduce the impact of COVID-19 in healthcare workers (BRACE) Trial ,2020-07-08,SARS-CoV-2 infection,"Version: 20.0, SOC Term: 100000004848, Classification Code: 10047490, Term: Virus identification and serology, Level: HLT",Adults,"Male, Female",NL(Completed) GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002503-19,,,,,
2020-001803-17,GS-US-540-5823,Gilead Sciences Inc.,"A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19",2020-07-14,Coronavirus disease 2019 (COVID-19),"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Newborns, Infants and toddlers, Children, Adolescents, Under 18","Male, Female",GB(GB - no longer in EU/EEA) IT(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17,,,,,
2020-003643-29,VAC31518COV3009,Janssen Vaccines & Prevention B.V.  ,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older  E...",2020-11-10,"Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19)","Version: 23.1, SOC Term: 100000004865, Classification Code: 10084465, Term: COVID-19 vaccination, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) FR(Ongoing) DE(Ongoing) ES(Temporarily Halted) BE(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003643-29,,,,,
2020-002211-21,SGS.1656.201,St George Street Capital Ltd,"A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCA...",2020-07-31,COVID-19,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) CZ(Completed) RO(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002211-21,,,,,
2020-002542-16,INSIGHT013,"Office of Sponsored Projects, Regents of the University of Minnesota","An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the...",2020-09-30,COVID-19 (SARS-CoV-2) infection,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) GR(Completed) DK(Completed) DE(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002542-16,,,,,
2020-003125-39,TRI-08892,Thrombosis Research Institute,"Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap...",2020-10-12,Confirmed diagnosis of SARS-CoV-2  with symptomatic COVID-19 infection ,,"Adults, Elderly","Male, Female",BE(Completed) GB(GB - no longer in EU/EEA) DE(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003125-39,,,,,
2020-001497-30,ALXN1210-COV-305,"Alexion Pharmaceuticals, Inc.","COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-1...",2020-05-07,"COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome","Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10061229, Term: Lung infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) FR(Prematurely Ended) DE(Prematurely Ended) ES(Prematurely Ended) IT(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001497-30,,,,,
2020-003368-24,MK-4482-002,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19",2020-11-18,COVID-19,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT","Adults, Elderly","Male, Female",FR(Completed) GB(GB - no longer in EU/EEA) DE(Completed) IT(Completed) PL(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003368-24,,,,,
2020-001689-12,MHIPS-2020-001,MONTREAL HEART INSTITUTE,COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19),2020-04-11,"Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion.",,"Adults, Elderly","Male, Female",ES(Ongoing) GB(GB - no longer in EU/EEA) FR(Prematurely Ended) GR(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12,,,,,
2020-001172-15,APN01-01-COVID19,APEIRON Biologics AG,Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19,2020-04-08,"Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age",,"Adults, Elderly","Male, Female",DE(Completed) DK(Completed) AT(Completed) GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15,,,,,
2020-003510-12,GS-US-540-9012,"Gilead Sciences, Inc","A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting",2020-10-02,COVID-19,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT","Adolescents, Under 18, Adults, Elderly","Male, Female",DK(Completed) GB(GB - no longer in EU/EEA) PT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003510-12,,,,,
2020-001662-11,CINC424J12301,Novartis Pharma AG,"Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)",2020-05-05,COVID-19 associated cytokine storm,,"Adolescents, Under 18, Adults, Elderly","Male, Female",DE(Completed) GB(GB - no longer in EU/EEA) FR(Completed) ES(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11,,,,,
2020-003367-26,MK4482-001,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19",2020-11-18,COVID-19,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT","Adults, Elderly","Male, Female",FR(Completed) GB(GB - no longer in EU/EEA) SE(Completed) PL(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003367-26,,,,,
2020-004356-16,D8850C00002,AstraZeneca AB,"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...",2020-11-18,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) BE(Ongoing) FR(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004356-16,,,,,
2020-001052-18,010,Regents of the University of Minnesota,"A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...",2020-03-25,Influenza COVID-19,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10022005, Term: Influenza viral infections, Level: HLT","Adults, Elderly","Male, Female",DK(Completed) GB(Completed) DE(Completed) GR(Completed) ES(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001052-18,,,,,
2020-001270-29,EFC16858,sanofi-aventis recherche & développement,"An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19",2020-04-08,Coronavirus infection,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",DK(Prematurely Ended) CZ(Prematurely Ended) DE(Prematurely Ended) GB(Prematurely Ended) FR(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29,,,,,
2020-001517-21,I4V-MC-KHAA,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection",2020-06-30,COVID-19 infection,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) DE(Completed) ES(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001517-21,,,,,
2020-001807-18,TD-0903-0188,Theravance Biopharma Ireland Limited ,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with...",2020-05-18,Acute lung injury associated with COVID-19,"Version: 20.1, SOC Term: 100000004855, Classification Code: 10047468, Term: Viral lower respiratory tract infections, Level: HLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) RO(Completed) FI(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001807-18,,,,,
2020-002632-75,CLI-050000-04,CHIESI FARMACEUTICI S.p.A,"Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf®) in hospitalized patients with SARS-COV-19 acute respiratory distr...",2020-07-08,patients with SARS-COV-19 acute respiratory distress syndrome (ARDS),,"Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) IT(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002632-75,,,,,
2020-001498-63,BIO101-CL05,Biophytis S.A.,"Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterior...",2020-07-22,Confirmed infection with SARS-CoV-2 (COVID-19),"Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10047465, Term: Viral infections NEC, Level: HLT","Adults, Elderly","Male, Female",FR(Completed) BE(Completed) GB(GB - no longer in EU/EEA) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001498-63,,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT",,,
2020-001154-22,WA42380,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.",2020-04-06,Severe COVID-19 pneumonia,"Version: 21.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035737, Term: Pneumonia viral, Level: PT","Adults, Elderly","Male, Female",DK(Completed) DE(Completed) FR(Completed) NL(Completed) GB(GB - no longer in EU/EEA) IT(Completed) ES(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001154-22,,,,,
2018-002069-21,D5180C00013,AstraZeneca AB,"A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C...",2018-10-23,Severe Asthma,"Version: 20.0, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10003553, Term: Asthma, Level: PT","Adults, Elderly","Male, Female",DK(Completed) GB(GB - no longer in EU/EEA) DE(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002069-21,,,,,
2020-001411-25,XPORT-COV-1001,Karyopharm Therapeutics Inc.,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection,2020-05-18,Severe COVID-19 Infection,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT","Adults, Elderly","Male, Female",DE(Completed) FR(Completed) AT(Completed) GB(GB - no longer in EU/EEA) ES(Temporarily Halted) IT(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25,,,,,
2020-003278-37,INSIGHT-014-ACTIV-3,Regents of the University of Minesota,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 ",2020-09-04,"Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19.","Version: 23.1, SOC Term: 10042613 - Surgical and medical procedures, Classification Code: 10084460, Term: COVID-19 treatment, Level: PT","Adults, Elderly","Male, Female",DK(Temporarily Halted) GB(GB - no longer in EU/EEA) SE(Prematurely Ended) PL(Ongoing) GR(Ongoing) IT(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003278-37,,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT",,,
2020-000842-32,GS-US-540-5774,"Gilead Sciences, Inc.",A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment,2020-03-18,Coronavirus disease 2019 (COVID-19),"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adolescents, Under 18, Adults, Elderly","Male, Female",DE(Completed) ES(Completed) FR(Completed) IT(Completed) NL(Completed) GB(Completed) SE(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000842-32,,,,,
2020-002979-35,209348,GlaxoSmithKline Research & Development Limited,"A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chron...",2020-12-22,Chronic Hepatitis B,"Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10008910, Term: Chronic hepatitis B, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) PL(Ongoing) IT(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002979-35,,,,,
2020-000841-15,GS-US-540-5773,"Gilead Sciences, Inc.",A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19,2020-03-18,Coronavirus disease 2019 (COVID-19),"Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT","Adolescents, Under 18, Adults, Elderly","Male, Female",DE(Completed) ES(Completed) FR(Completed) IT(Completed) NL(Completed) GB(Completed) SE(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000841-15,,,,,
2020-004743-83,SG018,Synairgen Research Limited,"A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19",2020-11-09,COVID-19,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) BE(Completed) PT(Completed) FR(Completed) NL(Completed) IT(Completed) DE(Completed) RO(Completed) ES(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83,,,,,
2020-001673-75,ABX464-401,ABIVAX,"A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu...",2020-05-06,COVID-19 infection (infection with SARS-CoV-2 virus),,"Adults, Elderly","Male, Female",FR(Prematurely Ended) DE(Completed) GB(GB - no longer in EU/EEA) ES(Prematurely Ended) BE(Prematurely Ended) IT(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75,,,,,
2020-001759-42,214094,GlaxoSmithKline Research & Development Limited,"A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.",2020-05-20,Severe pulmonary COVID-19 related disease,"Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) NL(Completed) ES(Completed) BE(Completed) DE(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001759-42,,,,,
2018-003898-94,BN40955,F.Hoffmann La-Roche Ltd,AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE ,2019-03-07,Huntington's disease (HD),"Version: 20.0, SOC Term: 10010331 - Congenital, familial and genetic disorders, Classification Code: 10070668, Term: Huntington's disease, Level: PT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ES(Temporarily Halted) NL(Completed) AT(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003898-94,,,,,
2017-004958-42,MOM-M281-003,"Momenta Pharmaceuticals, Inc.","A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ...",2019-01-11,Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN),"Version: 20.0, SOC Term: 100000004850, Classification Code: 10019512, Term: Hemolytic disease due to Rh isoimmunization of fetus or newborn, Level: LLT","In utero, Under 18, Adults",Female,GB(GB - no longer in EU/EEA) BE(Ongoing) NL(Ongoing) SE(Ongoing) ES(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004958-42,,,,,
2020-001370-30,CACZ885D2310,Novartis Pharma AG,"Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CA...",2020-04-29,COVID-19-induced pneumonia (CAN-COVID),"Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT","Adults, Elderly","Male, Female",DE(Completed) GB(GB - no longer in EU/EEA) FR(Completed) ES(Completed) HU(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30,,,,,
2018-000930-37,M15-722,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",2018-12-21,Ulcerative Colitis,"Version: 20.1, SOC Term: 100000004856, Classification Code: 10045365, Term: Ulcerative colitis, Level: LLT","Adults, Elderly","Male, Female",NL(Prematurely Ended) DE(Prematurely Ended) GB(GB - no longer in EU/EEA) FR(Prematurely Ended) ES(Completed) HU(Completed) IT(Prematurely Ended) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000930-37,,,,,
2015-002340-14,REMAP-CAP,University Medical Center Utrecht ,"Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)",2015-09-16,Severe Community Acquired Pneumonia,"Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10010120, Term: Community acquired pneumonia, Level: LLT","Adults, Elderly","Male, Female",NL(Ongoing) IE(Ongoing) PT(Ongoing) GB(GB - no longer in EU/EEA) HU(Ongoing) BE(Ongoing) DE(Ongoing) HR(Ongoing) ES(Temporarily Halted) FR(Ongoing) FI(Ongoing) IT(Ongoing) SI(Ongoing) RO(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14,,"Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT",,,
2017-001365-24,WN39658,Roche Farma S.A.(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F.Hoffmann-La Roche LTD,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER’S DISEASE",2018-06-05,Alzheimer’s Disease (AD),"Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10001897, Term: Alzheimer's disease (incl subtypes), Level: HLT","Adults, Elderly","Male, Female",ES(Ongoing) GB(GB - no longer in EU/EEA) DK(Ongoing) BE(Ongoing) PT(Ongoing) PL(Ongoing) NL(Ongoing) SE(Ongoing) FI(Ongoing) HR(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001365-24,,"Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10074616, Term: Prodromal Alzheimer's disease, Level: PT",,,
2019-000954-67,ATB200-07,"Amicus Therapeutics, Inc.",A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease,2020-04-08,Adult Subjects With Late Onset Pompe Disease (LOPD),"Version: 20.0, SOC Term: 100000004850, Classification Code: 10075702, Term: Pompe's disease late onset, Level: LLT","Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) ES(Ongoing) DE(Ongoing) DK(Ongoing) FR(Ongoing) BE(Ongoing) GR(Ongoing) SI(Ongoing) AT(Ongoing) IT(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000954-67,,,,,
2015-004726-34,SHP620-302,"Takeda Development Center Americas, Inc.","A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...",2017-09-01,Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients,"Version: 20.0, SOC Term: 100000004862, Classification Code: 10021819, Term: Infection in marrow transplant recipients, Level: LLT","Adolescents, Under 18, Adults, Elderly","Male, Female",HU(Completed) DE(Completed) GB(GB - no longer in EU/EEA) ES(Ongoing) BE(Completed) CZ(Completed) PL(Completed) FR(Completed) HR(Completed) IT(Ongoing) GR(Completed) AT(Completed) Outside EU/EEA ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004726-34,,,,,
2016-004676-22,M16-066,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who ...",2019-01-14,Ulcerative Colitis,"Version: 20.0, SOC Term: 10017947 - Gastrointestinal disorders, Classification Code: 10009900, Term: Colitis ulcerative, Level: PT","Adolescents, Under 18, Adults, Elderly","Male, Female",BE(Ongoing) SK(Ongoing) AT(Ongoing) ES(Ongoing) SE(Ongoing) NL(Ongoing) DK(Ongoing) GR(Ongoing) PL(Ongoing) DE(Ongoing) LT(Ongoing) PT(Ongoing) GB(GB - no longer in EU/EEA) LV(Ongoing) SI(Ongoing) BG(Ongoing) HR(Ongoing) FR(Not Authorised) IT(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004676-22,,,,,
2016-004719-10,AC-058B303,Actelion Pharmaceuticals Ltd.,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis",2017-10-02,relapsing multiple sclerosis,"Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10063400, Term: Secondary progressive multiple sclerosis, Level: PT",Adults,"Male, Female",ES(Ongoing) SE(Completed) PL(Ongoing) CZ(Ongoing) BG(Ongoing) LV(Ongoing) HU(Ongoing) LT(Ongoing) PT(Ongoing) HR(Ongoing) GB(GB - no longer in EU/EEA) FI(Ongoing) GR(Ongoing) RO(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004719-10,,"Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10063399, Term: Relapsing-remitting multiple sclerosis, Level: PT",,,
2019-002621-30,M19-063,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemi...",2020-06-10,Acute Myeloid Leukemia (AML),,"Adolescents, Under 18, Adults, Elderly","Male, Female",GB(GB - no longer in EU/EEA) FR(Ongoing) DE(Ongoing) CZ(Ongoing) ES(Ongoing) IT(Ongoing) HU(Ongoing) GR(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002621-30,,,,,
2016-002154-20,CLCZ696G2301,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk ...",2017-03-28,Left ventricular dysfunction following an acute myocardial infarction.,"Version: 20.0, SOC Term: 10007541 - Cardiac disorders, Classification Code: 10000891, Term: Acute myocardial infarction, Level: PT","Adults, Elderly","Male, Female",DE(Completed) PT(Completed) CZ(Completed) GB(GB - no longer in EU/EEA) GR(Completed) AT(Completed) SK(Completed) NL(Completed) ES(Completed) HU(Completed) BE(Completed) DK(Completed) SE(Completed) FI(Completed) BG(Completed) HR(Completed) IT(Completed) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002154-20,,,,,
2017-004703-51,COMB157G2399,Novartis Pharma AG,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis ",2019-01-10,Multiple sclerosis,"Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10048393, Term: Multiple sclerosis relapse, Level: PT",Adults,"Male, Female",DE(Ongoing) SK(Ongoing) HU(Ongoing) GB(GB - no longer in EU/EEA) NL(Ongoing) AT(Ongoing) FR(Ongoing) PT(Ongoing) ES(Ongoing) CZ(Ongoing) SE(Ongoing) LT(Ongoing) DK(Ongoing) FI(Ongoing) BE(Ongoing) LV(Ongoing) GR(Ongoing) HR(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004703-51,,,,,
2016-000674-38,M14-533,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)",2016-09-20,Ulcerative Colitis,"Version: 20.0, SOC Term: 10017947 - Gastrointestinal disorders, Classification Code: 10009900, Term: Colitis ulcerative, Level: PT","Adolescents, Under 18, Adults, Elderly","Male, Female",SK(Ongoing) NL(Ongoing) CZ(Ongoing) AT(Ongoing) FI(Ongoing) PL(Ongoing) SE(Completed) GB(GB - no longer in EU/EEA) DE(Ongoing) LV(Ongoing) GR(Ongoing) EE(Ongoing) IE(Ongoing) HU(Ongoing) PT(Ongoing) LT(Ongoing) BE(Ongoing) NO(Ongoing) ES(Ongoing) HR(Ongoing) IT(Ongoing) RO(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000674-38,,,,,
2016-002937-31,MA30143,F. Hoffmann-La Roche Ltd,"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis ",2017-09-12,Relapsing remitting multiple sclerosis (RRMS),"Version: 20.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10028245, Term: Multiple sclerosis, Level: PT",Adults,"Male, Female",NO(Ongoing) SE(Ongoing) AT(Completed) DK(Completed) DE(Ongoing) PT(Ongoing) BE(Ongoing) HU(Ongoing) PL(Ongoing) SK(Ongoing) ES(Ongoing) BG(Ongoing) SI(Ongoing) NL(Ongoing) GB(GB - no longer in EU/EEA) FR(Ongoing) HR(Ongoing) IT(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002937-31,,"Version: 21.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10063399, Term: Relapsing-remitting multiple sclerosis, Level: PT","Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10048393, Term: Multiple sclerosis relapse, Level: PT","Version: 20.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10039720, Term: Sclerosis multiple, Level: LLT",
2016-003191-50,M16-000,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease",2017-08-23,Crohn's disease,"Version: 20.0, SOC Term: 100000004856, Classification Code: 10013099, Term: Disease Crohns, Level: LLT","Adolescents, Under 18, Adults, Elderly","Male, Female",SK(Ongoing) DK(Ongoing) DE(Ongoing) PT(Ongoing) CZ(Ongoing) GB(GB - no longer in EU/EEA) LV(Ongoing) IE(Ongoing) BG(Ongoing) AT(Ongoing) PL(Ongoing) NL(Ongoing) EE(Ongoing) SE(Ongoing) ES(Ongoing) GR(Ongoing) NO(Ongoing) LT(Ongoing) BE(Ongoing) HR(Ongoing) FR(Ongoing) IT(Ongoing) RO(Ongoing) ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003191-50,,,,,
